Michael Grey compensation by year
Mirum Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2018 | FY2019 |
|---|---|---|
| Salary | $25,000 | $300,000 |
| Bonus | $0 | $150,000 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $5,212,396 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $25,000 | $5,662,396 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mirum Pharmaceuticals, Inc. DEF 14A filed January 1, 1900, accession 0001564590-20-019713, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Mirum Pharmaceuticals, Inc. filed document, accession 0001564590-20-019713. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 262,500 | — | $6.27 |
| Option | 265,624 | — | $2.94 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Mirum Pharmaceuticals, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
13 Form 4 lines since the FY2019 proxy (filed January 1, 1900)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-15 | Grant or award derivative | — | 1,980 | $0.00 | 1,980 |
| 2026-06-15 | Grant or award derivative | — | 3,772 | $0.00 | 3,772 |
| 2025-12-19 | Exercise or conversion | 10b5-1 | 50,000 | $2.94 | 50,000 |
| 2025-12-19 | Sale | 10b5-1 | 50,000 | $78.00 | 0 |
| 2025-12-19 | Exercise or conversion derivative | 10b5-1 | 50,000 | $0.00 | 181,176 |
| 2025-12-01 | Sale | 10b5-1 | 50,000 | $74.00 | 0 |
| 2025-12-01 | Exercise or conversion | 10b5-1 | 50,000 | $2.94 | 50,000 |
| 2025-12-01 | Exercise or conversion derivative | 10b5-1 | 50,000 | $0.00 | 231,176 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Mirum Pharmaceuticals’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Christopher Peetz | Chief Executive Officer and President (4) | $6,235,185 |
| Michael Grey · this page | Former Executive Chairman and Chief Executive Officer (2) | $5,662,396 |
| Pamela Vig | Chief Scientific Officer (6) | $2,681,958 |
| Lara Longpre | Chief Development Officer (6) | $2,526,658 |
Board service
Mirum Pharmaceuticals board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $110,000 | $174,988 | $174,855 | — | $459,843 |
| FY2024 | $108,750 | $149,989 | $149,774 | — | $408,513 |
| FY2023 | $105,000 | — | $346,747 | — | $451,747 |
| FY2022 | $103,750 | — | $278,299 | — | $382,049 |
| FY2021 | $100,000 | — | $197,379 | — | $297,379 |
Each year as the company reported it in Mirum Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Mirum Pharmaceuticals pays directors a $50,000 cash retainer and $300,000 in equity. As stated in Mirum Pharmaceuticals's FY2025 proxy.
Committees
Chairman of the Board (Chair)
The full Mirum Pharmaceuticals compensation record
free company briefThis page is one person within Mirum Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Mirum Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mirum Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.